Bluejay Diagnostics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Bluejay Diagnostics, Inc. on August 8, 2023. The company is incorporated in Delaware and its common stock trades on The NASDAQ Stock Market LLC under the symbol BJDX. The report addresses a specific regulatory matter regarding the company's listing status.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a listing compliance update.
Material Changes
The primary event reported is the resolution of a minimum bid price deficiency. On August 8, 2023, the company received notification from The Nasdaq Stock Market that it has regained compliance with Nasdaq Listing Rule 5550(a)(2). This compliance was achieved because the closing bid price of the company's common stock remained at least $1.00 per share for the required period. Consequently, the deficiency matter previously disclosed on October 25, 2022, is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No new risks or contingencies were disclosed in this report, other than the historical context of the previously resolved listing deficiency.
Key Facts for Investors
- Bluejay Diagnostics has regained compliance with Nasdaq's minimum bid price requirement ($1.00 per share).
- The listing deficiency matter initiated on October 25, 2022, is officially closed.
- This report does not include any new financial performance data or operational updates.